Skip to main content
Universe Pharmaceuticals INC logo

Universe Pharmaceuticals INC — Investor Relations & Filings

Ticker · UPC ISIN · KYG9442G1047 US Manufacturing
Open in API
Filings indexed 99 across all filing types
Latest filing 2023-08-31 Interim / Quarterly Rep…
Country US United States of America
Listing US UPC

About Universe Pharmaceuticals INC

http://www.universe-pharmacy.com/

Universe Pharmaceuticals INC is a pharmaceutical company specializing in the manufacturing, marketing, sales, and distribution of traditional Chinese medicine (TCM) derivative products. Through its subsidiaries, the company's product portfolio also includes biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces (TCMPs), and dietary supplements.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Universe Pharmaceuticals INC, reporting financial results for the six months ended March 31, 2023. It includes unaudited condensed interim consolidated financial statements and Management's Discussion and Analysis (MD&A). Form 6-K is used for interim or current reports by foreign private issuers and typically contains quarterly or semi-annual financial data. The presence of MD&A and interim financial statements indicates this is an Interim / Quarterly Report. The document length is 5265 characters, which is sufficient to contain substantive financial data, not just an announcement. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2023-08-31 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It contains a notification about Nasdaq compliance regarding the minimum bid price requirement. The content is an update on regulatory compliance rather than a full financial report or detailed earnings data. The document length is short (2528 characters) and it primarily serves as a regulatory announcement. It does not contain financial statements or detailed management discussion. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-08-16 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about a Nasdaq notification regarding minimum market value of publicly held shares. The document is short (1413 characters) and does not contain detailed financial statements or substantive financial data. It is an announcement/report filing rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-08-04 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about a share consolidation, but the document length is only 1437 characters, indicating it is a brief announcement rather than a full report. The content does not contain detailed financial statements or substantive financial data. It is primarily a regulatory filing to inform about a corporate action (share consolidation). According to the rules, such filings that do not fit other categories and are brief announcements fall under Regulatory Filings (RNS).
2023-07-27 English
REPORT OF FOREIGN PRIVATE ISSUER
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 6-K filed by Universe Pharmaceuticals INC, reporting the results of the 2023 Annual General Meeting (AGM). It details the voting outcomes on various proposals including director re-elections, share capital increase, share consolidation, and amendments to the memorandum of association. The content is focused on the official results of shareholder votes at the AGM, which aligns with the category for Declaration of Voting Results & Voting Rights Announcements (DVA). The document is over 7,000 characters and contains detailed voting results, not just an announcement of a report or a brief summary. Therefore, it is not a Report Publication Announcement or a Regulatory Filing. It is not a management or board change announcement, nor a financial report or earnings release. Hence, the best classification is DVA with high confidence.
2023-07-05 English
CURRENT REPORT
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a current report filed by foreign private issuers to the SEC. It includes exhibits related to the Notice and Proxy Statement for the 2023 Annual General Meeting (AGM) and a Form of Proxy Card. The document itself is a filing to furnish these materials, not the materials themselves or the AGM meeting content. The length is short (1817 characters), and it primarily announces the proxy materials to be mailed to shareholders. According to the rules, such a document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement and does not contain the full AGM materials or the actual meeting content. It is not an AGM Information (AGM-R) filing because it does not contain the presentations or materials themselves, only a notice of their distribution.
2023-05-24 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.